TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04623151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online leaflet about foot care
Description: Short text-based leaflet about foot care, presented online

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online leaflet about foot care
Description: Short text-based leaflet about foot care, presented online
Study: NCT03940534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAD
Description: TAD is a device used to aid medication adherence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAD
Description: TAD is a device used to aid medication adherence.
Study: NCT00432120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
Study: NCT03942445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrocnemius muscle biopsy
Description: In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
Study: NCT04318886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENABLE Cornerstone
Description: The ENABLE (Educate, Nurture, Advise, Before Life Ends) Cornerstone intervention is led by a specially-trained lay coach who is overseen by an interdisciplinary outpatient palliative care team, who employs health coaching techniques and caregiver distress assessment to behaviorally activate and reinforce psychoeducation on managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning over 6 brief in-person/telephonic sessions plus monthly follow-up from diagnosis through early bereavement.
Study: NCT03586193

Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy
Description: pars plana vitrectomy without ICG staining and ILM peeling
Study: NCT04208711

Intervention type: OTHER
Group type: OTHER
Intervention: biological sample
Description: whole blood sample
Study: NCT02004795

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BNCT + IG-IMRT
Description: Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
Study: NCT03805048

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
Study: NCT03357055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV infusion of 0.25mg/kg of ketamine over 10 minutes before pneumatic tourniquet inflation. Throughout procedure patient will receive 0.25mg/kg of ketamine infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
Study: NCT03234452

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoflorene plus
Description: 2 vials with dosing cap (10 mL) a day per os

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lactoflorene plus
Description: 2 vials with dosing cap (10 mL) a day per os
Study: NCT02940379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Pharmaceutical form: HCl syrup~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Pharmaceutical form: HCl syrup~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02499315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 357
Description: Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Study: NCT03474744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Solution for IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Solution for IV infusion
Study: NCT01922011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: IV daptomycin Infusion A in 12 to \<18 years old (7 mg/kg); in 7 to \< 12 year olds (9 mg/kg); in 24 months to \<7 year olds (12 mg/kg); in 12 to \<24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (or equivalent)
Description: IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nafcillin (or equivalent)
Description: IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
Study: NCT05141994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5mg of BAT5906
Description: Specification: 2.5mg of BAT5906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg of BAT5906
Description: Specification: 4mg of BAT5906
Study: NCT02664883

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Correlative studies

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and urine samples

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and urine samples

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and urine samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Correlative studies
Study: NCT00357162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study: NCT04180930

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5
Description: Clinician Administered PTSD Scale for DMS-5

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5
Description: Clinician Administered PTSD Scale for DMS-5

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-5
Description: Clinician Administered PTSD Scale for DMS-5

Intervention type: DIAGNOSTIC_TEST
Intervention: PSSI-5
Description: PTSD Symptom Scale Interview for DSM-5

Intervention type: DIAGNOSTIC_TEST
Intervention: PSSI-5
Description: PTSD Symptom Scale Interview for DSM-5

Intervention type: DIAGNOSTIC_TEST
Intervention: CAPS-IV
Description: Clinician Administered PTSD Scale for DSM-IV
Study: NCT03757793

Intervention type: DEVICE
Intervention: FORE-SIGHT ELITE monitor
Description: At end of surgery, one sensor of the FORE-SIGHT Elite monitor is placed on the DIEP flap or two sensors in case of bilateral DIEP flaps for monitoring perfusion and oxygen consumption in the free flap. A control sensor of the FORE-SIGHT Elite monitor placed on the abdomen where tissue is taken to perform the DIEP flap. This sensor reflects normal tissue oxygenation. Data obtained from the FORE-SIGHT Elite monitor will be compared to data obtained from physical examination, which is standard of care for flap monitoring.
Study: NCT01859741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-59R5
Description: OMP-59R5 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-59R5
Description: OMP-59R5 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: administered intravenously
Study: NCT02447029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal 2% Xylocaine
Description: patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block

Intervention type: DRUG
Group type: OTHER
Intervention: standard lidocaine paracervical block
Description: 1% lidocaine paracervical injection
Study: NCT02011334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg will be administered once weekly by subcutaneous injection.
Study: NCT01053936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (amorphous dispersion)
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (amorphous dispersion)
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (amorphous dispersion)
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (amorphous dispersion)
Description: Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (amorphous dispersion)
Description: Oral, once daily
Study: NCT00315822

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 80% oxygen
Description: Supplemental oxygen will be administered during surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 30% oxygen
Description: Subjects undergoing surgery will receive routine administration of oxygen
Study: NCT01601795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: volatile Anaesthetic, duration during cardiopulmonary bypass

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: volatile anesthetic, duration during cardiopulmonary bypass time
Study: NCT04447365

Intervention type: DIAGNOSTIC_TEST
Intervention: device interrogation
Description: All patients will have a pre-existing ICD and a diagnosis of cardiomyopathy with left ventricular systolic function of 35% or less by echocardiogram done within 3 years of the time of enrollment.

Intervention type: DIAGNOSTIC_TEST
Intervention: device interrogation
Description: All patients will have a pre-existing ICD and a diagnosis of cardiomyopathy with left ventricular systolic function of 35% or less by echocardiogram done within 3 years of the time of enrollment.
Study: NCT01257542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single 10 mL dose of matching placebo syrup
Study: NCT03147287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is a drug that may stop cancer cells from growing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is a drug that may stop cancer cells from growing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
Study: NCT01058824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lincomycin
Description: Single Dose Hard Gelatin Capsule - oral - 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lincomycin
Description: Single Dose Hard Gelatin Capsule - oral - 500 mg
Study: NCT00790933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion
Study: NCT04278092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2, q21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400mg/m2 loading dose followed by weekly 250mg/m2
Study: NCT01567800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Description: PET scan with the radiolabelled tracer 18F-FAZA
Study: NCT00792480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle counseling
Description: The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise.
Study: NCT03837834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation Leg Cycling Exercise
Description: FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation Leg Cycling Exercise
Description: FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.
Study: NCT03651219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
Study: NCT00561353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
Study: NCT01295892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: transdermal 17-β-estradiol 1mg/day during three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estrogen
Description: transdermal 17-β-estradiol 1mg/day during three months
Study: NCT03611127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: pulmonary rehabilitation standardized program
Study: NCT02265744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Study: NCT03651219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
Study: NCT00322439

Intervention type: DRUG
Intervention: Etanercept
Description: Observational study - no drug administered
Study: NCT04533594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NOVELA
Description: The family caregivers that consent to participate will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the telenovela video (one of four episodes, each 3-6 mins) over the course of 4 hospice visits (one episode per visit). All four visits will be in person using telehealth via video-conferencing. The number of visits is based on the number of videos which content is prioritized based on previous work. The interventionist will introduce the purpose and topic of the video, facilitate video viewing and then elicit clarifying questions and reinforce main message.
Study: NCT00992147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipocell
Description: autologous cultured adipocytes (ANTG-adip)
Study: NCT03810118

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fluid challenge
Description: 4 ml/kg fluid challenge infused over in either 10 or 20 minutes
Study: NCT03463850

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dual Energy CT (DECT)
Description: Dual Energy CT (DECT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dual Energy CT (DECT)
Description: Dual Energy CT (DECT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DEXA
Description: Dual-energy x-ray absorptiometry for measurement of bone mineral density

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DEXA
Description: Dual-energy x-ray absorptiometry for measurement of bone mineral density
Study: NCT01721850

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control formula
Description: commercial stage 1 infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention formula 1
Description: infant formula with hydrolyzed protein (type I) and pre- and probiotics
Study: NCT02265744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-931699
Study: NCT01721850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention formula 2
Description: infant formula with hydrolyzed protein (type II) and pre- and probiotics
Study: NCT05721586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Assembling Peptide P11-4 (CURODONTTM REPAIR) + Fluoride varnish (DURAFLOR
Description: The WSL was Acid etched with phosphoric acid gel 35-37% for 20 seconds, the tooth surface was rinsed with water and then dried afterwards application of CURODONTTM REPAIR

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride varnish (DURAFLOR
Description: A very thin coat of the DURAFLOR varnish was applied by a thin brush which was then allowed to dry for 10 seconds. The varnish hardens on contact with saliva or moisture
Study: NCT03733314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: E6011, infusion, intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, infusion, intravenously.
Study: NCT02004197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple Allopathic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadruple Allopathic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pylorex plus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pylorex plus
Study: NCT01375920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metyrapone
Description: 500 milligrams to be taken twice a day orally
Study: NCT02265744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-931699